Loading…
Prostate Research, Outreach, Screening, Testing, Access, and Treatment Effectiveness Act of 2010
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 4,048 other S bills in the 111th — cohort avg 29d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2010 · fourth_quarter · Health Issues
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $380,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Client expense: $440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE